Abstract: AIM To explore the clinical significance of changes of chemerin and EDA-fibronectin(EDA-FN) in serum of patients with atherosclerosis(AS). METHODS One hundred and two AS patients were divided into severe AS group(sAS group) and mild AS group(mAS group) according to the degree of AS. Fifty healthy subjects were included as normal control group(normal group). ELISA was used to measure the contents of chemerin and EDA-FN in serum of the three groups. RESULTS Contents of chemerin and EDA-FN in serum of the sAS and mAS groups were significantly higher than those in the normal control group(P<0.05). Contents of chemerin and EDA-FN in serum of the sAS group were significantly higher than those in the mAS group(P<0.05). CONCLUSION Levels of chemerin and EDA-FN in serum of AS patients increase significantly compared with those in healthy subjects and the levels are positively correlated with the degree of AS. Detecting the contents of chemerin and EDA-FN in serum is helpful in clinical diagnosis and prognosis of AS patients.